--(BUSINESS WIRE)--Acucela Inc., is a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596) committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide. Acucela’s development pipeline include drug candidates and therapeutics for the treatment of retinitis pigmentosa, proliferative diabetic retinopathy, diabetic macular edema, AMD, Stargardt disease, cataracts and presbyopia. The company is also developing a monitoring device for neovascular retinal diseases, to be used directly by patients.
| Company: | Acucela Inc. | |
| Headquarters Address: | 818 Stewart St., Suite 1110 | |
| Seattle, WA 98101 | ||
| Main Telephone: |
1-206-805-8300 |
|
| Website: | ||
| Type of Organization: | Private | |
|
Industry: |
Biotechnology, Medical Devices, Pharmaceutical |
|
| Key Executives: | CEO: Ryo Kubota, MD, PhD | |
| Public Relations | ||
| Contact: | Michael Hasegawa | |
| Phone: |
+81-3-6550-8928 |
|
| Email: | ||
| Investor Relations | ||
| Contact: | John Gebhart | |
| Phone: | +1-206-805-3972 | |
| Email: | ||
